Tibet Aim Pharm Inc (SHE:002826) — Market Cap & Net Worth
Market Cap & Net Worth: Tibet Aim Pharm Inc (002826)
Tibet Aim Pharm Inc (SHE:002826) has a market capitalization of $475.17 Million (CN¥3.25 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12630 globally and #3708 in its home market, demonstrating a -3.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tibet Aim Pharm Inc's stock price CN¥17.03 by its total outstanding shares 190677750 (190.68 Million). Also see Tibet Aim Pharm Inc assets under control for a full breakdown of the balance sheet.
Tibet Aim Pharm Inc Market Cap History: 2016 to 2026
Tibet Aim Pharm Inc's market capitalization history from 2016 to 2026. Data shows growth from $702.23 Million to $475.17 Million (7.55% CAGR). Also see 002826 cash flow conversion for how efficiently the company converts equity into cash flow.
Tibet Aim Pharm Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tibet Aim Pharm Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Tibet Aim Pharm Inc (002826) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.81x
Tibet Aim Pharm Inc's market cap is 0.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.54x
Tibet Aim Pharm Inc's market cap is 5.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $702.23 Million | $451.92 Million | $55.36 Million | 1.55x | 12.69x |
| 2017 | $398.16 Million | $380.29 Million | $60.48 Million | 1.05x | 6.58x |
| 2018 | $274.66 Million | $488.77 Million | $25.26 Million | 0.56x | 10.88x |
| 2019 | $272.53 Million | $553.26 Million | $37.33 Million | 0.49x | 7.30x |
| 2020 | $263.95 Million | $602.62 Million | $41.09 Million | 0.44x | 6.42x |
| 2021 | $298.79 Million | $725.46 Million | $42.48 Million | 0.41x | 7.03x |
| 2022 | $280.72 Million | $856.73 Million | $44.14 Million | 0.33x | 6.36x |
| 2023 | $330.07 Million | $667.04 Million | $15.39 Million | 0.49x | 21.45x |
| 2024 | $289.07 Million | $651.88 Million | $45.93 Million | 0.44x | 6.29x |
| 2025 | $512.84 Million | $636.27 Million | $92.58 Million | 0.81x | 5.54x |
Competitor Companies of 002826 by Market Capitalization
Companies near Tibet Aim Pharm Inc in the global market cap rankings as of September 19, 2026. Review 002826 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tibet Aim Pharm Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Tibet Aim Pharm Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Tibet Aim Pharm Inc's market cap moved from $702.23 Million to $ 475.17 Million, with a yearly change of 7.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥475.17 Million | -7.34% |
| 2025 | CN¥512.84 Million | +77.41% |
| 2024 | CN¥289.07 Million | -12.42% |
| 2023 | CN¥330.07 Million | +17.58% |
| 2022 | CN¥280.72 Million | -6.05% |
| 2021 | CN¥298.79 Million | +13.20% |
| 2020 | CN¥263.95 Million | -3.15% |
| 2019 | CN¥272.53 Million | -0.78% |
| 2018 | CN¥274.66 Million | -31.02% |
| 2017 | CN¥398.16 Million | -43.30% |
| 2016 | CN¥702.23 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Tibet Aim Pharm Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $475.17 Million USD |
| MoneyControl | $475.17 Million USD |
| MarketWatch | $475.17 Million USD |
| marketcap.company | $475.17 Million USD |
| Reuters | $475.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more